Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019

K. Hebeda, L. Boudova, C. Beham-Schmid, A. Orazi, HM. Kvasnicka, U. Gianelli, A. Tzankov

. 2021 ; 100 (1) : 117-133. [pub] 20201031

Jazyk angličtina Země Německo

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011637

Disease progression in myelodysplastic syndromes (MDS) and myelodysplastic-myeloproliferative neoplasms (MDS/MPN) is a major source of mortality. The European Bone Marrow Working Group organized a dedicated workshop to address MDS and MDS/MPN progression, and myeloid neoplasms with histiocytic and lymphoblastic outgrowths in 2019 in Frankfurt, Germany. In this report, we summarize clinical, histopathological, and molecular features of 28 cases. Most cases illustrate that prognostic mutational profiles change during follow-up due to accumulation of high-risk mutations in the trunk clone, and that results from repeated molecular testing can often explain the clinical progression, suggesting that regular genetic testing may predict transformation by early detection of aggressive clones. Importantly, identical mutations can be linked to different clinical behaviors or risks of fibrotic progression and/or transformation in a context-dependent manner, i.e., MDS or MDS/MPN. Moreover, the order of mutational acquisition and the involved cell lineages matter. Several cases exemplify that histiocytic outgrowths in myeloid neoplasms are usually accompanied by a more aggressive clinical course and may be considered harbinger of disease progression. Exceptionally, lymphoblastic transformations can be seen. As best estimable, the histiocytic and lymphoblastic compounds in all occasions were clonally related to the myeloid compound and-where studied-displayed genomic alterations of, e.g., transcription factor genes or genes involved in MAPK signaling that might be mechanistically linked to the respective type of non-myeloid outgrowth.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011637
003      
CZ-PrNML
005      
20210507101600.0
007      
ta
008      
210420s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-020-04307-9 $2 doi
035    __
$a (PubMed)33128619
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Hebeda, Konnie $u Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands
245    10
$a Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019 / $c K. Hebeda, L. Boudova, C. Beham-Schmid, A. Orazi, HM. Kvasnicka, U. Gianelli, A. Tzankov
520    9_
$a Disease progression in myelodysplastic syndromes (MDS) and myelodysplastic-myeloproliferative neoplasms (MDS/MPN) is a major source of mortality. The European Bone Marrow Working Group organized a dedicated workshop to address MDS and MDS/MPN progression, and myeloid neoplasms with histiocytic and lymphoblastic outgrowths in 2019 in Frankfurt, Germany. In this report, we summarize clinical, histopathological, and molecular features of 28 cases. Most cases illustrate that prognostic mutational profiles change during follow-up due to accumulation of high-risk mutations in the trunk clone, and that results from repeated molecular testing can often explain the clinical progression, suggesting that regular genetic testing may predict transformation by early detection of aggressive clones. Importantly, identical mutations can be linked to different clinical behaviors or risks of fibrotic progression and/or transformation in a context-dependent manner, i.e., MDS or MDS/MPN. Moreover, the order of mutational acquisition and the involved cell lineages matter. Several cases exemplify that histiocytic outgrowths in myeloid neoplasms are usually accompanied by a more aggressive clinical course and may be considered harbinger of disease progression. Exceptionally, lymphoblastic transformations can be seen. As best estimable, the histiocytic and lymphoblastic compounds in all occasions were clonally related to the myeloid compound and-where studied-displayed genomic alterations of, e.g., transcription factor genes or genes involved in MAPK signaling that might be mechanistically linked to the respective type of non-myeloid outgrowth.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kostní dřeň $x patologie $7 D001853
650    _2
$a nádorová transformace buněk $x genetika $x patologie $7 D002471
650    12
$a progrese nemoci $7 D018450
650    _2
$a výchova a vzdělávání $x metody $7 D004493
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myelodysplastické syndromy $x genetika $x patologie $7 D009190
650    _2
$a myelodysplasticko-myeloproliferativní nemoci $x genetika $x patologie $7 D054437
651    _2
$a Evropa $7 D005060
651    _2
$a Německo $7 D005858
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Boudova, Ludmila $u Bioptická laboratoř, Pilsen, Czech Republic
700    1_
$a Beham-Schmid, Christine $u Institute of Pathology, Medical University of Graz, Graz, Austria
700    1_
$a Orazi, Attilio $u Department of Pathology, Texas Tech Health Sciences Center El Paso, El Paso, TX, USA
700    1_
$a Kvasnicka, Hans-Michael $u Institute of Pathology, Helios University Hospital, Wuppertal, Germany
700    1_
$a Gianelli, Umberto $u Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan and Fondazione IRCCS, Ca' Granda-Maggiore Policlinico, Milan, Italy
700    1_
$a Tzankov, Alexandar $u Institute of Medical Genetics and Pathology, University Hospital of Basel, Schoenbeinstrasse 40, CH-4031, Basel, Switzerland. Alexandar.Tzankov@usb.ch
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 100, č. 1 (2021), s. 117-133
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33128619 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101600 $b ABA008
999    __
$a ok $b bmc $g 1650105 $s 1132016
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 100 $c 1 $d 117-133 $e 20201031 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace